GlobeNewswire Inc.··NaNurix Therapeutics Posts $87.2M Loss While Advancing Bexobrutideg Clinical Pipeline
Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.
SNYGILDNRIXclinical trialsimmunology